Shares of Merck & Co. Inc. MRK slid 1.72% to $96.24 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.88% to 6,049.24 and ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’ Substack by Magnus Ofstad. In this ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...

Analysts fell to the sidelines weighing in on Inspire Medical Systems (INSP – Research Report) and Merck & Company (MRK – Research Report) ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Shares of this pharmaceutical company have returned +1.2% over the past month versus the Zacks S&P 500 composite's -1.6% change. The Zacks Large Cap Pharmaceuticals industry, to which Merck ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.